SkinHealth Systems Inc. reported a net loss of $0.9 million for the third quarter of 2026, an improvement from an $11.0 million loss in the prior year period, driven by reduced operating expenses. Total assets decreased significantly from $499.8 million at year-end 2025 to $389.1 million as of September 30, 2026, primarily due to a reduction in cash used for the repayment and repurchase of convertible senior notes.
SkinHealth Systems reported third quarter 2026 financial results, with net sales of $69.2 million and a significantly narrowed net loss of $0.9 million compared to $11.0 million in the prior year. The company highlighted a return to growth in consumables and improved adjusted EBITDA margins as it executes on strategic priorities for its flagship Hydrafacial brand.
Term
Q3 2026
“Our third quarter results reflect encouraging progress in strengthening our business. Revenue trends improved, consumables returned to growth, and we delivered healthy adjusted EBITDA performance. While we have more work ahead, these results give us greater confidence that the actions we are taking are moving the business in the right direction.”
Pedro Malha, President and Chief Executive Officer
SkinHealth Systems Inc. implemented a 1-for-20 reverse stock split of its Class A Common Stock, effective October 14, 2026. The action is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces the outstanding share count from approximately 130.3 million to 6.5 million shares.
SkinHealth Systems $103M Debt Financing with U.S. Bank National Association
SkinHealth Systems Inc. repaid in full the remaining $103.2 million aggregate principal amount of its 1.25% Convertible Senior Notes due 2026. Following the payment of principal and accrued interest, the related indenture was satisfied and discharged, releasing the company from its obligations under the notes.
SkinHealth Systems stockholders approved an amendment to the company's Restated Certificate of Incorporation to implement a reverse stock split of its Class A Common Stock. The approved ratio range is between 1-for-5 and 1-for-20, with the final ratio to be determined by the board of directors.